10.01.08
A new research study funded by the National Institutes of Health (NIH) showed that ChromeMate, InterHealth Nutraceutical’s patented niacin-bound chromium complex, significantly reduced vascular inflammation, while chromium picolinate did not.
The 8-week study looked at blood markers for vascular inflammation, including TNF-a, MCP-1, retinol binding protein-4 (RBP-4), cholesterol and triglycerides in obese Zucker diabetic rats. The diets of test animals were supplemented with 400 mcg of chromium (III) from ChromeMate or chromium picolinate per kilogram of body weight.
When compared with animals in the control group, the ChromeMate group experienced significantly lower total cholesterol and triglycerides than the group supplemented with chromium picolinate. Levels of TNF-a MCP-1, RBP-4 were also lower in the ChromeMate group compared to the control group; the chromium picolinate group did not experience any reduction in those markers.
For further information: 800-783-4636.
The 8-week study looked at blood markers for vascular inflammation, including TNF-a, MCP-1, retinol binding protein-4 (RBP-4), cholesterol and triglycerides in obese Zucker diabetic rats. The diets of test animals were supplemented with 400 mcg of chromium (III) from ChromeMate or chromium picolinate per kilogram of body weight.
When compared with animals in the control group, the ChromeMate group experienced significantly lower total cholesterol and triglycerides than the group supplemented with chromium picolinate. Levels of TNF-a MCP-1, RBP-4 were also lower in the ChromeMate group compared to the control group; the chromium picolinate group did not experience any reduction in those markers.
For further information: 800-783-4636.